Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

3

Revenue 2017

MabThera/Rituxan

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

NICE recommends Roche’s Polivy for B-cell lymphoma

NICE recommends Roche’s Polivy for B-cell lymphoma

drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL). ... In a clinical trial of patients with DLBCL, Polivy plus Rituxan/bendamustine produced a 40% complete response

Roche cites COVID-19 and biosimilars in Q2 decline

Roche cites COVID-19 and biosimilars in Q2 decline Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

Celgene’s Revlimid scores NICE approval in follicular lymphoma

Celgene’s Revlimid scores NICE approval in follicular lymphoma Revlimid (lenalidomide) has been recommended for use with Roche’s MabThera (rituximab) – also known as R2 regimen – for the treatment of adult patients with previously-treated grade 1 to 3A follicular ... Revlimid plus MabThera demonstrated a

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Roche posts minor sales miss in Q4 as biosimilar pressure grows All told, the Swiss group’s pharma sales came in at CHF 12bn ($12.35bn), with its ‘big three’ antibodies – Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan/MabThera (rituximab) – all on the

Mylan, Biocon’s Herceptin biosimilar launched in US

Mylan, Biocon’s Herceptin biosimilar launched in US Alongside Herceptin, this includes Avastin (bevacizumab) and MabThera (rituximab) which are also under threat from new biosimilar launches.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics